Brink of a new era

Au­to­mated de­liv­ery sys­tems likely to be­come stan­dard for pro­duc­tion units of all sizes

Fish Farmer - - Aqua Nor preview - BY RON­NIE SOUTAR

OVER the last year and a bit, I’ve had the hon­our of be­ing pres­i­dent of the Fish Vet­eri­nary So­ci­ety.Among other things, that has led to me be­ing in­volved, on be­half of the sal­monid aqua­cul­ture sec­tor, in dis­cus­sions on an­tibi­otic re­sis­tance in live­stock, and its re­la­tion­ship to the use and avail­abil­ity of an­tibi­otics in hu­man medicine.

My in­volve­ment has been no hard­ship at all, as we have a good story to tell.The in­tro­duc­tion of ef­fec­tive vac­cines against the ma­jor bac­te­rial dis­eases, par­tic­u­larly fu­run­cu­lo­sis, way back in the 1990s has meant that our an­tibi­otic us­age has re­mained min­i­mal.

We al­ready eas­ily meet the goals be­ing set for the re­duc­tion in an­tibi­otic us­age in other farmed species.

This, along­side the fact that the bac­te­ria which in­fect salmon are quite dif­fer­ent from those which af­fect hu­mans, means that we can rightly claim to be well ahead with the One Health agenda, which aims to min­imise the im­pact of dis­ease in hu­man and an­i­mal pop­u­la­tions.

How­ever, there is no room for com­pla­cency. Emerg­ing bac­te­rial dis­eases in the fresh­wa­ter phase could well mean us reach­ing for those an­tibi­otics which are crit­i­cally im­por-

with­out its prob­lems. In­tra-peri­toneal oil-ad­ju­vanted vac­cines do cause side qual­ity or the (gen­uine) as­sur­ance that there is no risk to hu­man health from

against sea lice has yet to ap­pear, we have been vac­ci­nat­ing against viruses pre­ven­tion of dis­eases for which there is no treat­ment, they have to date not pro­duced the level of pro­tec­tion we’ve come to ex­pect of the bac­te­rial vac­cines.

vac­cines and vac­ci­na­tion.The in­ter­est in this sec­tor is ev­i­denced by re­cent on­go­ing com­pe­ti­tion for mar­ket share be­tween MSD, Elanco and Zoetis.

New play­ers are also en­ter­ing the frame – I’m aware of Bench­mark An­i­mal Health and Hipra in that con­text and I’m sure there are oth­ers.

There has also been a con­sid­er­able in­crease in the pro­duc­tion of au­to­ge­nous vac­cines by the likes of Ridge­way in the UK andVaxxi­nova in Nor­way, rep­re­sent­ing the ‘rapid re­sponse’ end of the mar­ket.All of this is good news

In terms of vac­cine tech­nol­ogy, ex­cit­ing de­vel­op­ments are on-go­ing.As I Elanco’s pan­creas dis­ease vac­cine ap­pears to rep­re­sent a true in­no­va­tion, with in­tra-mus­cu­lar vac­ci­na­tion in­tro­duc­ing a whole new as­pect to the process.

Other com­pa­nies are work­ing on RNA vac­cines and it would ap­pear to be only a mat­ter of time be­fore th­ese new style vac­cines be­come the norm.

Vac­cine de­liv­ery will have to change to adapt – ini­tially, at least, com­pa­nies such as Aqual­ife will have to de­velop meth­ods to in­ject two vac­cines, into dif hard be­hind the scenes to en­sure this can be done, so the chal­lenge is largely al­ready ad­dressed.

vac­ci­na­tion by teams of skilled work­ers re­mains very im­por­tant – it still forms the ma­jor part of the work for Aqual­ife.

How­ever, ma­chine vac­ci­na­tion con­tin­ues to de­velop and fully au­to­mated vac­ci­na­tion be­came a re­al­ity with the in­tro­duc­tion of Skala Maskon’s ground-break­ing ma­chine.

I think, though, that we’re on the brink of a whole new era of au­to­mated

As the sec­tor moves rapidly for­ward, we have to en­sure it does so in a wel­fare friendly man­ner”

vac­ci­na­tion, as robotic tech­nol­ogy be­comes es­tab­lished in our in­dus­try.This has been the cen­tral fo­cus of R&D at Aqual­ife and I know that oth­ers are equally in­ter­ested.

It seems in­evitable that au­to­mated vac­cine de­liv­ery sys­tems will be­come stan­dard for pro­duc­tion units of all sizes within a very short time.

In all of th­ese de­vel­op­ments, we do have to re­mem­ber what we’re try­ing na­tion process, or the vac­cines them­selves, to have a neg­a­tive im­pact. That is

The im­por­tance of qual­ity con­trol in the de­vel­op­ment of vac­cines and vac­ci­na­tion tech­nol­ogy, and in the man­age­ment of the vac­ci­na­tion process, can­not be over em­pha­sised.

As the sec­tor moves rapidly for­ward, we have to en­sure it does so in a harm’!


Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.